(Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time.

摘要: How do experts judge the legitimacy of technical policy processes, and their ideas change as these processes are opened to other stakeholders public? This research examines adoption public patient involvement in pharmaceutical assessment Canada. It finds tensions between scientific that prioritizes rigor objectivity, democratic values inclusion a broader range evidence. In response change, incorporate new about inputs while maintaining goals. The responds calls for more precise measurement ideational evaluation health policy. helps us understand significance of, limits to, among domains highly publicly salient. Understanding way negotiated decisions has wide applicability health, but is particularly relevant during global pandemic when evidence being generated rapidly, must be made quickly, have significant, immediate effect on lives all citizens.